Searchable abstracts of presentations at key conferences in endocrinology

ea0074ncc48 | Highlighted Cases | SFENCC2021

The pragmatic use of corticosteroids in the diagnosis and treatment of non-PTH driven hypercalcaemia

Yousif Yasear Zainab Akram , Ijaz Nadia , Gittoes Neil , Sanders Anna , Pang Terence

A 65-year-old gentleman was referred by his GP because of acute kidney injury and hypercalcaemia, which was associated with low levels of parathyroid hormone. He had been fit and well and was on no regular medications. Whilst his hypercalcaemia was partly correctible with saline rehydration, cautious use of bisphosphonates and cinacalcet were not effective in preventing rebound, and his nephropathy persisted. Curiously, he had longstanding low plasma alkaline phosphatase, but had normal denti...

ea0026s16.1 | TSH Receptor and thyroid disorders | ECE2011

TSH-receptor antibodies

Sanders J

TSHR autoantibodies with stimulating (agonist) activity cause the hyperthyroidism of Graves’ disease, while the rarer blocking (antagonist) type TSHR autoantibodies are responsible for hypothyroidism in some patients. We have isolated four human monoclonal autoantibodies (MAbs) which bind the TSHR with high affinity. Two antibodies, M22 and K1-18 have potent thyroid stimulating activity, one MAb K1-70 has strong antagonist (blocking) activity and the fourth MAb 5C9 has st...

ea0011p40 | Bone | ECE2006

Does parathyroidectomy reduce the risk of fractures and renal stones? Results of a systematic review and meta analysis

Sanders BE , Davies M , Selby PL

Primary hyperparathyroidism (PHP) is a common endocrine condition. The associated metabolic abnormalities are usually amenable to surgical treatment (PTX). Although it is generally believed that such treatment will reduce the risk of long-term complications this has not been demonstrated in a clinical trial and the current treatment guidelines are based on consensus. In order to assess the effect of parathyroidectomy on two of the most common complications of PHP, renal stones...

ea0035oc6.3 | Bone, calcium & vitamin D | ECE2014

Hypoparathyroidism: The burden of illness and impact on patients' personal lives

Clarke Bart , Sanders James , Lagast Hjalmar

Hypoparathyroidism, a rare endocrine disorder of insufficient parathyroid hormone, leads to hypocalcemia and often hyperphosphatemia. The PARADOX study assessed the clinical and personal disease impact from the affected patients’ perspective.Patients ≥18 years and diagnosed ≥6 months ago completed a non-validated, self-reported, web-based survey.Three hundred and seventy-four US adults (mean age, 49 years; women, 8...

ea0070aep20 | Adrenal and Cardiovascular Endocrinology | ECE2020

Transcriptomic profiling of canine adrenocortical tumors

Sanders Karin , Van Steenbeek Frank , Galac Sara

Adrenocortical carcinoma (ACC) is an aggressive cancer, with, in its advanced stages, a median 5-year survival rate of less than 15%. ACC is rare in humans, but in dogs the incidence is at least 100 times higher. Because these dogs receive medical care, have an intact immune system, and have inter-individual and intratumoral heterogeneity, the dog is a unique spontaneous animal model to study new treatment options for ACC. However, to determine similarity of canine and human A...

ea0011p312 | Diabetes, metabolism and cardiovascular | ECE2006

A case of myocardial infarction induced by factitious hypoglycaemia in type 2 diabetes patient

Srinivasan R , Sanders E , Flynn M

Introduction: Insulin is widely used in Type 2 patients to control the blood sugar when the oral hypoglycaemic agents fail. This is a case report of a type 2 diabetes patient who developed Myocardial Infarction after factitious hypoglycaemia with insulin.Case report: A 64-year-old gentleman with known Ischaemic Heart Disease was treated with insulin (Mixtard 30) and metformin for his type 2 diabetes. He presented to diabetes Specialist nurse with persist...

ea0084ps3-12-109 | Graves’ Disease 2 and Orbitopathy | ETA2022

Blocking the TSH receptor with human monoclonal autoantibody K1-70TM in patients with graves’ disease – results from a phase 1 clinical trial

Furmaniak Jadwiga , Sanders Jane , Sanders Paul , Li Yang , Rees Smith Bernard

Objectives: TSH receptor (TSHR) autoantibodies (TRAb) which mimic the actions of TSH are responsible for hyperthyroidism in Graves’ disease (GD) which is often associated with Graves’ orbitopathy (GO). K1-70 is a TSHR specific human monoclonal autoantibody which binds to the TSHR with high affinity and prevents stimulation of the TSHR by TSH and TRAb. Safety, tolerability, pharmacokinetic, pharmocodynamic and immunogenic effects of K1-70 in patients with GD were asse...

ea0077op5.4 | Bone and Calcium | SFEBES2021

Normocalcaemic hyperparathyroidism: Impact of assay and reference range differences on the diagnosis

Fenn Jonathan , Kalaria Tejas , Sanders Anna , Ford Clare , Gama Rousseau

Approximately 70% of clinical laboratories in the United Kingdom use assays from Abbott Laboratories and Roche Diagnostics. We carried out a cross-sectional study between two neighbouring hospital laboratories in our regional pathology network, comparing the potential impact of Abbott and Roche PTH and calcium assays in the diagnosis of normocalcaemic hyperparathyroidism. Over 4 months, forty-one vitamin D replete (>50 nmol/l) normocalcaemic hyperparathyroidism patients (3...

ea0029p1113 | Neuroendocrinology | ICEECE2012

Retinal growth hormone: local regulation by GH-releasing hormone (GHRH)?

Harvey S. , Qiang W. , Lin W. , Sanders E.

Introduction: The (GH) gene, identical to that in the pituitary, is expressed in retinal ganglion cells (RGCs) in chickens, rats, mice and humans. Retinal GH is a neuroprotective factor, as it promotes RGC survival and, in humans, the concentration of GH in vitreous fluid may be a marker for ocular disease. Increasing retinal GH expression could thus have therapeutic potential. The factors regulating retinal GH expression are, however, unknown. The possibility that GH-releasin...